WCM Investment Management LLC Has $6.58 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

WCM Investment Management LLC boosted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 49.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 263,679 shares of the company's stock after acquiring an additional 86,987 shares during the quarter. WCM Investment Management LLC owned 0.14% of BridgeBio Pharma worth $6,576,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in shares of BridgeBio Pharma by 189.7% during the first quarter. Janus Henderson Group PLC now owns 3,312,706 shares of the company's stock worth $102,402,000 after purchasing an additional 2,169,143 shares during the period. Capital Research Global Investors boosted its stake in shares of BridgeBio Pharma by 101.1% during the 1st quarter. Capital Research Global Investors now owns 2,212,085 shares of the company's stock valued at $68,398,000 after buying an additional 1,111,975 shares during the period. Ensign Peak Advisors Inc grew its holdings in shares of BridgeBio Pharma by 44.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 1,646,202 shares of the company's stock valued at $41,698,000 after acquiring an additional 506,845 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of BridgeBio Pharma by 40.5% in the second quarter. The Manufacturers Life Insurance Company now owns 1,534,972 shares of the company's stock worth $38,881,000 after acquiring an additional 442,248 shares during the last quarter. Finally, Emerald Advisers LLC raised its holdings in shares of BridgeBio Pharma by 65.6% during the third quarter. Emerald Advisers LLC now owns 1,103,508 shares of the company's stock worth $28,095,000 after acquiring an additional 437,164 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now directly owns 25,260,971 shares in the company, valued at $650,470,003.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the completion of the transaction, the chief financial officer now owns 85,192 shares in the company, valued at approximately $2,103,390.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,831,544 shares of company stock worth $150,128,821 in the last ninety days. 24.66% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BBIO has been the topic of a number of recent research reports. Evercore ISI lowered their target price on BridgeBio Pharma from $50.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. Oppenheimer started coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They issued a "market perform" rating on the stock. Scotiabank began coverage on shares of BridgeBio Pharma in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $44.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 16th. Finally, Bank of America restated a "buy" rating and set a $42.00 price target on shares of BridgeBio Pharma in a report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $47.50.

BridgeBio Pharma Stock Down 5.7 %

NASDAQ BBIO traded down $1.50 during trading on Tuesday, hitting $24.62. The company's stock had a trading volume of 2,425,162 shares, compared to its average volume of 1,842,451. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $44.32. The firm has a market cap of $4.63 billion, a P/E ratio of -9.93 and a beta of 1.09. The firm has a 50 day moving average price of $25.98 and a 200 day moving average price of $26.45.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.